These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6515702)

  • 1. Binding of amantadine to red blood cells.
    Daugirdas JT; Ing IL; Cheng PJ; Wu MJ; Klawans HL; Soung LS
    Ther Drug Monit; 1984; 6(4):399-401. PubMed ID: 6515702
    [No Abstract]   [Full Text] [Related]  

  • 2. Removal of amantadine hydrochloride by dialysis in patients with renal insufficiency.
    Ing TS; Mahurkar SD; Dunea G; Hayashi JA; Klawans HL; Markey WS
    Can Med Assoc J; 1976 Sep; 115(6):515. PubMed ID: 953934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amantadine toxicity in a patient with renal insufficiency.
    Armbruster KF; Rahn AC; Ing TS; Halper IS; Oyama JH; Klawans HL
    Nephron; 1974; 13(2):183-6. PubMed ID: 4850491
    [No Abstract]   [Full Text] [Related]  

  • 4. Plasma protein-binding of amantadine in maintenance hemodialysis patients.
    Ing TS; Cheng PJ; Wu MJ; Daugirdas JT; Soung LS
    Int J Artif Organs; 1984 Jul; 7(4):235. PubMed ID: 6490196
    [No Abstract]   [Full Text] [Related]  

  • 5. Plasma amantadine concentrations in patients with Parkinson's disease.
    Nishikawa N; Nagai M; Moritoyo T; Yabe H; Nomoto M
    Parkinsonism Relat Disord; 2009 Jun; 15(5):351-3. PubMed ID: 18823813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function.
    Horadam VW; Sharp JG; Smilack JD; McAnalley BH; Garriott JC; Stephens MK; Prati RC; Brater DC
    Ann Intern Med; 1981 Apr; 94(4 pt 1):454-8. PubMed ID: 7212501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous application of amantadine and antiparkinsonian efficacy in Parkinsonian patients.
    Müller T; Kuhn W; Quack G; Przuntek H
    J Neural Transm Suppl; 1995; 46():407-13. PubMed ID: 8821076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic experiences with amantadine sulfate as a monotherapeutic drug in patients with Parkinsonism].
    Völler GW; Deze J
    Z Allgemeinmed; 1973 May; 49(14):664-70. PubMed ID: 4585272
    [No Abstract]   [Full Text] [Related]  

  • 9. Amantadine-induced coma.
    Macchio GJ; Ito V; Sahgal V
    Arch Phys Med Rehabil; 1993 Oct; 74(10):1119-20. PubMed ID: 8215867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of amantadine on drug-induced parkisonism: relationship between plasma levels and effect.
    Pacifici GM; Nardini M; Ferrari P; Latini R; Fieschi C; Morselli PL
    Br J Clin Pharmacol; 1976 Oct; 3(5):883-9. PubMed ID: 788761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence of an increased susceptibility to lipid peroxidation in red blood cells of chronic renal failure patients.
    Miguel A; Miguel A; Linares M; Perez A; Moll R; Sanchis J; Escobedo JM; Miguel-Borja JM
    Nephron; 1988; 50(1):64-5. PubMed ID: 3173606
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic brain concentration of the NMDA receptor antagonist amantadine.
    Kornhuber J; Quack G; Danysz W; Jellinger K; Danielczyk W; Gsell W; Riederer P
    Neuropharmacology; 1995 Jul; 34(7):713-21. PubMed ID: 8532138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Experience in the prolonged use of midantan (amantadine hydrochloride) in parkinsonism].
    Man'kovskii NB; Vainshtok AB; Oleinik LI
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(4):524-30. PubMed ID: 4705407
    [No Abstract]   [Full Text] [Related]  

  • 14. Simultaneous determination of memantine and amantadine in human plasma as fluorescein derivatives by micellar electrokinetic chromatography with laser-induced fluorescence detection and its clinical application.
    Yeh HH; Yang YH; Chen SH
    Electrophoresis; 2010 Jun; 31(11):1903-11. PubMed ID: 20446294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.
    Metman LV; Del Dotto P; LePoole K; Konitsiotis S; Fang J; Chase TN
    Arch Neurol; 1999 Nov; 56(11):1383-6. PubMed ID: 10555659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered mental status in a transplant patient. Amantadine toxicity.
    Michalski LS; Hantsch Bardsley C; Holt DR; Milner JE; Hou SH
    Kidney Int; 2009 Jan; 75(2):243-4. PubMed ID: 19116645
    [No Abstract]   [Full Text] [Related]  

  • 17. [Intravenous and oral treatment with amantadine sulfate in Parkinson disease].
    Brenner M; Haass A; Jacobi P; Schimrigk K
    Nervenarzt; 1988 Mar; 59(3):180-4. PubMed ID: 3374720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Heinz body formation and abnormal methemoglobin reduction. Expressions of damage to erythrocytes in chronic kidney failure].
    Grieger M; Rapoport S
    Haematologia (Budap); 1976; 10(2):157-68. PubMed ID: 1030681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic amantadine dose and plasma concentration-effect relationships in healthy adults.
    Aoki FY; Stiver HG; Sitar DS; Boudreault A; Ogilvie RI
    Clin Pharmacol Ther; 1985 Feb; 37(2):128-36. PubMed ID: 3967455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amantadine enhancement of L-DOPA induced growth hormone stimulation.
    Massara F; Camanni F; Molinatti GM
    Horm Metab Res; 1973 Nov; 5(6):454-6. PubMed ID: 4767002
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.